Top Markets
Coin of the day
Nicox S.A. Nicox S.A.

Nicox S.A.

COX
Rank in Stocks #34243
Nicox S.A. is an ophthalmology enterprise operating both within France and... Nicox S.A. is an ophthalmology enterprise operating both within France and globally, focused on developing therapies to safeguard vision and enhance overall eye health. Its leading investigational drug, NCX 470, an innovative nitric oxide-donating prostaglandin analog designed to decrease intraocular pressure in individuals with open-angle glaucoma or ocular hypertension, is currently undergoing Phase 3 clinical trials. Furthermore, the company is progressing NCX 4251, a specialized fluticasone formulation, through a Phase 2b clinical trial for the management of acute exacerbations of blepharitis, as well as NCX 1728. Nicox also provides VYZULTA, a latanoprostene bunod ophthalmic solution for treating open-angle glaucoma or ocular hypertension, and ZERVIATE, a cetirizine ophthalmic solution to relieve ocular itching related to allergic conjunctivitis. The company, established in 1996, has its main office situated in Valbonne, France.
Share Price
$0.6379482
Last synced: 2023-05-22
Market Cap
$5.98M
Change (1 day)
-0.44%
Change (1 year)
0.00%
Country
FR
Trade Nicox S.A. (COX)

Category

Stock split history for Nicox S.A. (COX)
Nicox S.A. stock (symbol: COX) underwent a total of 0 stock splits.
The most recent stock split occurred on Aug 16, 2026.
One COX share bought prior to Aug 16, 2026 would equal to 0 COX shares today.
Stock split list
Year Split Multiple Cumulative Multiple
Not enough data for the provided dates.
Stock splits for similar companies or competitors
Company Number of stock splits Cumulative Multiple Country
1 x2
US
0 -
NL
0 -
CH
0 -
KR
0 -
BE